Daiichi Sankyo and Terumo Announce Application in Japan for Manufacturing and Sales Approval of Intradermal Seasonal Influenza Vaccine

April 10, 2015

Daiichi Sankyo Company, Limited

Terumo Corporation

Tokyo, Japan, April 10, 2015 - Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) and Terumo Corporation (hereafter, Terumo) today announced that Japan Vaccine Co., Ltd. (hereafter, Japan Vaccine), an affiliated company of Daiichi Sankyo, has filed an application for the manufacture and sales approval in Japan for an intradermal seasonal influenza vaccine (hereafter, The Vaccine).

The Vaccine is a pre-filled syringe type, intradermal influenza HA vaccine*1 co-developed by four companies [Daiichi Sankyo, Terumo, Japan Vaccine and Kitasato Daiichi Sankyo Vaccine Co., Ltd (hereafter, Kitasato Daiichi Sankyo)] under a February 23, 2012, agreement between Daiichi Sankyo and Terumo for the co-development of an intradermal vaccine for infectious diseases.

Terumo developed the intradermal injection*2 device, which offers a more easy-to-use, surefire method to administer the vaccine than current methods. The device is also expected to ease patient hesitation to be injected and lower the risk of damaging peripheral blood vessels and nerves within the subcutaneous tissue.

Daiichi Sankyo is committed to contributing to further the prevention of seasonal influenza through The Vaccine, as well as contributing to the protection of people's health by working to promote and enrich the preventive treatment environment and improve hygiene through the production of practical vaccines which meet medical demands.

Terumo aims to provide a new value to the medical front by combining high specialties in both pharmaceutical products and medical devices. Through these innovative developments, Terumo aims to establish itself as a company with a global presence in the medium to long-term.

  • *1

    An intradermal injection device developed by Terumo, which is a combination of a pre-fillable syringe with a needle specially designed for intradermal injection, pre-filled with influenza HA vaccine developed by Kitasato Daiichi Sankyo.

  • *2

    Recent study reports improved antigen-recognition by the immune system and enhanced effect of the vaccine through intradermal vaccine injection. (Hickling JK, Jones KR, Friede M, Zehrung D, Chen D, Kristensen D: Intradermal delivery of vaccines: potential benefits and current challenges. Bull World Health Organ 89: 221-226, 2011.)

Image of intradermal injection

(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.

Print
T
O
P